Page 4 - While Moderna News Today

By Parsa Erfani, Lawrence O. Gostin, and Vanessa Kerry May 19, 2021Reprints CRISTINA QUICLER/AFP via Getty Images The Biden administration’s announcement to support an intellectual property (IP) waiver for Covid-19 vaccines was a monumental step toward improving the access to them in low- and middle-income countries. But without further action, it will be little more than a symbol. The waiver allows companies to produce Covid-19 vaccines without fear of being sued by the entity that holds t...

  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500. [Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challeng...

Author Bio Taylor Carmichael is a former attorney and filmmaker. Hes the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool. While Moderna (NASDAQ:MRNA) is famous for its COVID-19 vaccine, the biotech actually has a vast development pipeline for many other mRNA vaccines. This year, all the revenues are going to come from vaccinatin...

The company said it expects to reduce the number of days taken to produce a batch of COVID-19 vaccines from 110 to around 60.

Moderna's CEO Stéphane Bancel tells Axios the company's coronavirus vaccine made it to market in near-record time thanks in part to a unique digital foundation.The big picture: Moderna is far smaller than many of its pharma competitors, but it made one of the first authorized COVID-19 vaccines. But the company still needs to adapt to a mutating virus — and come up with its next blockbuster product.Support safe, smart, sane journalism. Sign up for Axios Newsletters here.What...

Updated Monday, 25th January 2021, 4:07 pm While Moderna has said that its vaccine is effective against the new Covid-19 strains, a booster shot is in development (Photo: CHANDAN KHANNA/AFP via Getty Images) Dr Anthony Fauci, the top US infectious disease expert, has revealed that scientists in the US are preparing to upgrade Covid-19 vaccines in order to address the variants of the virus which are circulating in the UK and South Africa. As Dr Fauci made this announcement, producer Moderna sta...

  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500. [Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challeng...

Thursday, January 7, 2021 Stifling creativity, chilling innovation, and now even killing people: the EU needs to rethink its approach to industrial policy With VaxGate, Brussels--as a metonym for the EU--is going through its worst credibility crisis ever, while Brexit is already a success story in one particularly important regard: the UK is outvaccinating the Continent. Its also a fact that British elite universities outperform their continental counterparts in global rankings. Even EU-friendl...

As we've said before, Moderna's Covid-19 vaccine is likely to emerge as the most sought after vaccine in developed markets, considering its stellar efficacy rates and relative ease of storage.